Clinical Trials · NCT00225979
Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 100
- Start date
- Nov 2002
- Locations
- See registry
- Primary endpoint
- Mean GH and IGF-I at baseline, week 12, 24 and 48